3Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992,101 : 1644-1655.
4Barie PS, Hydo LJ, Shou J, et al. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect (Larchmt), 2006,7 Suppl 2: $77-80.
5Zanotti S, Kumar A, Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs, 2002,11 : 1061-1075.
6Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest, 2000,118 : 146-155.
7Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis, 2000,31 Suppl 4:S131-138.
8Schein M, Hirshberg A, Hashmonai M. Current surgical management of severe intraabdominal infection. Surgery, 1992,112:489-496.
9Stephan F, Hollande J, Richard O, et al. Thrombocytopenia in a surgical ICU. Chest, 1999,115 : 1363-1370.
10Nijsten MW, ten Duis H J, Zijlstra JG, et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med, 2000,28 : 3843-3846.
